Therefore, we also confirmed in vivo that inhibiting the PI3K/AKT-mTOR-FAS signaling could specifically trigger anti-tumor effects and downregulate Treg infiltration in the TIME of the GC model with CLDN18-ARHGAP fusion. The gene discussed is MTOR; the disease is neoplasm.